about us

Milestones

2021

mRNA vaccine enters trials

2019

Sanand Injectables facility commenced USFDA approval of Sanand and F-II (API).
TENECTASE approved as emergency care for stroke

2017

Set up facility at Sikkim/Bangalore

2016

Acquired Bharadwaj Pharma GMBH in Germany

2015

Acquired Marcan Pharmaceuticals Inc., Canada

2014

Acquired Tillomed Laboratories, United Kingdom.
Bain capital acquired Blackstone’s stake in Emcure

2012

Worldwide rights of BICNU acquired.
Commenced EU operations with formation of Emcure UK

2010

Cytotoxic facility commenced in Hinjewadi

2009

Solid Dosage facility commenced in Jammu

2007

USFDA approvals received for injectable facility at Hinjewadi.
First in-house biosimilar TNK-Tpa launched

2006

Blackstone’s first investment in India at Emcure.
API facility at Kurkumbh commenced.
Injectable & Emcure Biotech Ltd. (now Gennova biopharmaceuticals limited) facility operational

2005

Solid Oral Facility at Hinjewadi commenced & first USFDA approval granted

2004

Emcure Pharmaceutical USA (now Heritage Pharmaceutical Labs) incorporated & in-house API R&D commenced

2002

Zuventus Healthcare Limited incorporated & First Chiral product launched

2001

Gennova Biopharmaceuticals Limited incorporated

1995

Launched Indian Formulation Business

1983

First manufacturing facility operational in Bhosari

1981

Emcure Pharmaceuticals Private Limited incorporated

Know More About Us

Quick Explore

Left Nav
Right Nav